Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Roos, Izanne, Sharmin, Sifat, Malpas, Charles, Ozakbas, Serkan, Lechner-Scott, Jeannette, Hodgkinson, Suzanne, Alroughani, Raed, Eichau Madueño, Sara, Boz, Cavit, van der Walt, Anneke, Butzkueven, Helmut, Buzzard, Katherine, Skibina, Olga, Foschi, Matteo, Grand?Maison, Francois, John, Nevin, Grammond, Pierre, Terzi, Murat, Prévost, Julie, Barnett, Michael, Laureys, Guy, Van Hijfte, Liesbeth, Luis Sanchez-Menoyo, Jose, Blanco, Yolanda, Oh, Jiwon, McCombe, Pamela, Ramo Tello, Cristina, Soysal, Aysun, Prat, Alexandre, Duquette, Pierre, Yamout, Bassem I., Khoury, Samia, van Pesch, Vincent, Macdonell, Richard, José Sá, Maria, Slee, Mark, Kuhle, Jens, Maimone, Davide, Spitaleri, Daniele L.A., Willekens, Barbara, Asmi, Abdallah Al, Tallantyre, Emma ORCID: https://orcid.org/0000-0002-3760-6634, Robertson, Neil P. ORCID: https://orcid.org/0000-0002-5409-4909, Coles, Alasdair, L Brown, J. William and Kalincik, Tomas 2024. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal 30 (9) , pp. 1163-1175. 10.1177/13524585241267211

Preview

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview

Abstract

Background: Comparisons between cladribine and other potent immunotherapies for multiple sclerosis (MS) are lacking. Objectives: To compare the effectiveness of cladribine against fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting MS. Methods: Patients with relapsing-remitting MS treated with cladribine, fingolimod, natalizumab, ocrelizumab or alemtuzumab were identified in the global MSBase cohort and two additional UK centres. Patients were followed for ⩾6/12 and had ⩾3 in-person disability assessments. Patients were matched using propensity score. Four pairwise analyses compared annualised relapse rates (ARRs) and disability outcomes. Results: The eligible cohorts consisted of 853 (fingolimod), 464 (natalizumab), 1131 (ocrelizumab), 123 (alemtuzumab) or 493 (cladribine) patients. Cladribine was associated with a lower ARR than fingolimod (0.07 vs. 0.12, p = 0.006) and a higher ARR than natalizumab (0.10 vs. 0.06, p = 0.03), ocrelizumab (0.09 vs. 0.05, p = 0.008) and alemtuzumab (0.17 vs. 0.04, p < 0.001). Compared to cladribine, the risk of disability worsening did not differ in patients treated with fingolimod (hazard ratio (HR) 1.08, 95% confidence interval (CI) 0.47–2.47) or alemtuzumab (HR 0.73, 95% CI 0.26–2.07), but was lower for patients treated with natalizumab (HR 0.35, 95% CI 0.13–0.94) and ocrelizumab (HR 0.45, 95% CI 0.26–0.78). There was no evidence for a difference in disability improvement. Conclusion: Cladribine is an effective therapy that can be viewed as a step up in effectiveness from fingolimod, but is less effective than the most potent intravenous MS therapies.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Publisher:	SAGE Publications
ISSN:	1352-4585
Date of First Compliant Deposit:	29 August 2024
Date of Acceptance:	1 August 2024
Last Modified:	08 Nov 2024 02:15
URI:	https://orca.cardiff.ac.uk/id/eprint/171654

Actions (repository staff only)

Edit Item